Join
Live feed
·
PRReleasevia Quantisnow
Senti Biosciences Inc. logo

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

ByQuantisnow·Wall Street's wire, on your screen.
SNTI· Senti Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNTI (Senti Biosciences Inc.) and more on Quantisnow.